Skip to: Content
Skip to: Site Navigation
Skip to: Search

December 3, 2008 2:26:56 AM CST



Glaxo Stems Stock Slide Over Avandia

Posted May 31, 07 6:44 AM CDT in Business Science & Health US 

(Newser) – Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks.  A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence of heart attacks among Avandia patients—0.6%—was still very small.

And he said it was comparable to two other "gold standard" medicines used to treat type 2 diabetes. GlaxoSmithKline was up 50 cents in trading yesterday, but only after panic among investors wiped $21 billion off its market cap.The diabetes drug accounts for only 7% of Glaxo's shares, the Telegraph reports, suggesting the dive was an overreaction. 

Source Daily Telegraph (UK)

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon
« Prev« Prev | Next »Next » Slideshow
Our editors also recommend:

Defending Avandia

Threads (
1
 of 4)



Loading...

Premium Articles from HighBeam

Find more articles like this

Today's Most Popular

Loading...

Other US Stories


What is Newser?

2008 Codie Finalist

Face it: there's too much news. At Newser a team of editors and writers culls the most important stories from hundreds of U.S. and international sources and reduces them to a headline, picture, and two paragraphs. It's the Newser guarantee: we can take any report or column or video and pack what you need to know into 120 words or less. Newser's short-form aggregation, visual format, and unique information tools help you get more of the kind of news you want, in a quicker and more entertaining way. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »